Although we have found a significant amelioration of demyelination-associated neuropathy in C22 mice by targeted mutagenesis of TATA-box of PMP22, administration of therapeutic CRISPR at p6 could be a prevention rather than treatment. Here, PMP22 is linked to neuropathy.